News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Failure to ensure that everyone has access to prevention options to protect oneself from HIV acquisition, has resulted in at ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...
The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...
Imagine a world where an HIV prevention method lasts for six months, offering protection without the daily hassle of taking a ...
Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
Daily Maverick on MSN10d
Efficacy of six-monthly HIV prevention jab confirmed in second major studyIn June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback